Santarus Inc.
10590 West Ocean Air Drive
Suite 200
San Diego
California
92130
United States
Tel: 858-314-5700
Fax: 858-314-5701
Website: http://www.santarus.com/
Email: contact@santarus.com
230 articles about Santarus Inc.
-
Arbitral Tribunal Decides In Favor Of Valeant In UCERIS Arbitration
4/12/2018
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today announced that the Arbitral Tribunal issued a decision (rendered on April 9, 2018) relating to the arbitration between Santarus Inc. and Valeant Pharmaceuticals Ireland (collectively "Valeant"), and Cosmo Technologies Ltd. and Cosmo Technologies III Ltd. (collectively, "Cosmo"), the licensor of certain intellectual property rights in, and supplier of, Valeant's UCERIS® extended release tablets.
-
Salix Pharmaceuticals, Ltd. Completes Acquisition Of Santarus Inc.
1/3/2014
-
Santarus Inc. Announces Availability Of Amended Tender Offer Materials
12/30/2013
-
Santarus Inc. Initiates Phase IIa Study With SAN-300 In Patients With Active Rheumatoid Arthritis
12/23/2013
-
Salix Pharmaceuticals, Ltd. Announces Expiration Of Hart-Scott-Rodino Waiting Period For Acquisition Of Santarus Inc.
12/10/2013
-
Salix Pharmaceuticals, Ltd. Commences Cash Tender Offer For All Outstanding Shares Of Santarus Inc.
12/3/2013
-
Santarus Inc. Reports Third Quarter 2013 Financial Results
11/8/2013
-
Santarus Inc. and Pharming Group Announce New Data From Open-Label Repeat Treatment Study With RUCONEST (Recombinant Human C1 Esterase Inhibitor)
11/8/2013
-
Salix Pharmaceuticals, Ltd. Bags Santarus Inc. for $2.6 Billion to Beef Up Gastro Drug Line-Up
11/8/2013
-
Pharming Group and Santarus Inc. Announce New Data From Open-Label Repeat Treatment Study With Rucomest
11/8/2013
-
Santarus Inc. to Hold Third Quarter 2013 Financial Results Conference Call on November 7
10/28/2013
-
Santarus Inc. Announces Presentation of SAN-300 Phase I Data at 2013 American College of Rheumatology Annual Meeting
10/25/2013
-
Santarus Inc. Announces Presentation of Phase III Data for Rifamycin SV MMX in Travelers’ Diarrhea
10/4/2013
-
Santarus Inc. Announces Presentation of Phase 3 Data for Rifamycin SV MMX in Travelers’ Diarrhea
10/4/2013
-
Santarus Inc. to Present at September Investment Conferences
9/4/2013
-
Pharmaceutical Companies Announce Quarterly Financial Results - Research Report on Jazz Pharmaceuticals plc, ACADIA Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., Santarus Inc., and Incyte Corporation
8/9/2013
-
Santarus Inc. Reports Second Quarter 2013 Financial Results
8/7/2013
-
Santarus Inc. to Hold Second Quarter 2013 Financial Results Conference Call on August 6
7/23/2013
-
Santarus Inc. Completes Patient Enrollment in CONTRIBUTE Study With UCERIS (budesonide) as Add-On Treatment to 5-ASA Drugs
7/18/2013
-
Santarus Inc. to Present at JMP Securities Healthcare Conference
7/2/2013